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Abstract 
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in 
gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of 
non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients 
using [68Ga]Pentixafor in comparison to 68Ga-DOTA-D-Phe-Tyr3-octreotide ([68Ga]DOTATOC) and 
18F-fluorodeoxyglucose ([18F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) 
underwent [68Ga]DOTATOC, [18F]FDG, and [68Ga]Pentixafor PET/CT for staging and planning of the therapeutic 
management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical 
staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [68Ga]Pentixafor visualized tumor 
lesions in 6/12 subjects, whereas [18F]FDG revealed sites of disease in 10/12 and [68Ga]DOTATOC in 11/12 
patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 
NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited 
[68Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting 
well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor 
grade. Thus, [68Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of 
CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors. 
Key words: Neuroendocrine tumor, [68Ga]Pentixafor, CXCR4, chemokine receptor, PET/CT, SSTR, DOTATOC, 
PRRT, peptide receptor radionuclide therapy. 
Introduction 
Gastro-entero-pancreatic neuroendocrine 
tumors (GEP-NET) comprise a heterogeneous group 
of neoplasms originating from the endocrine cells of 
the intestinal tract. On the basis of tumor grade 
(assessed by mitotic rate as well as Ki67 index), 
GEP-NET are histologically separated into 
well-differentiated tumors of low grade (G1), 
intermediate grade (G2), and poorly differentiated 
high grade (G3) neuroendocrine tumors (NET) [1, 2]. 
Most likely due to improved staging sensitivity and 
shifts in pathological classification, a marked overall 
increase in NET incidence over the last 20 years from 
2.1/100,000/year to 4.9/100,000/year with the most 









1.8/100,000/year was recently reported [3]. 
Treatment options for well-differentiated, 
somatostatin receptor (SSTR)-expressing NET 
including biological agents (e.g. somatostatin 
analogs), conventional as well as peptide receptor 
radionuclide therapy (PRRT) have distinctly 
improved survival over the last decade [4-6]. 
However, treatment with (radiolabeled) SSTR analogs 
is generally not useful for G3 tumors, which do not 
express these receptors in an appropriate frequency 
and magnitude [7]. As a consequence, treatment 
response in case of tumor dedifferentiation and 
subsequent loss of SSTR expression is still poor, 
especially after failure to 1st line platinum-based 
chemotherapy [8, 9]. Hence, new therapeutic 
strategies in this setting are urgently needed. 
Overexpression of C-X-C motif chemokine 
receptor 4 (CXCR4) and its ligand stromal cell derived 
factor 1α (SDF-1α) has been shown to play a pivotal 
role in several types of cancer including NET [10-12]. 
Recently, Wester and coworkers developed the 
theranostic agents [68Ga]Pentixafor and [177Lu]/ 
[90Y]Pentixather for non-invasive assessment of 
CXCR4 expression and subsequent chemokine- 
directed endoradiotherapy (ERT) [13-23].  
Given the limited treatment options in case of 
dedifferentiation, identification of robust receptor 
expression on the tumor cell surface might pave the 
way for CXCR4-targeted ERT in SSTR-negative 
patients. Therefore, we aimed to evaluate this 
theranostic approach in NET using [68Ga]Pentixafor- 
PET/CT in comparison to [68Ga]DOTATOC and 
[18F]fluorodeoxyglucose ([18F]FDG). Imaging findings 
were also correlated with histological receptor 
expression derived from tumor samples. 
Material and Methods 
[68Ga]Pentixafor was administered on a 
compassionate use basis in compliance with §37 of the 
Declaration of Helsinki and The German Medicinal 
Products Act, AMG §13.2b. Routine staging or 
restaging examinations included [18F]FDG and 
SSTR-directed PET with [68Ga]DOTATOC. All 
patients underwent imaging for clinical purposes and 
gave written and informed consent to the diagnostic 
procedures. The study was approved by the local 
institutional review board of Würzburg (IRB 
approval: 2016100701). 
Patients 
From July 2015 till August 2016, a total of 12 
patients (10 male, 2 female, median age, 68 years, 
range, 48 – 82) suffering from histologically proven 
GEP-NET were included. At the time point of 
imaging, all patients had not received treatment for at 
least 4 weeks. Except a single patient, all subjects 
presented with an Eastern Cooperative Oncology 
Group (ECOG)/ World Health Organization (WHO) 
performance status ≤2 [24]. 
Preparation of [68Ga]Pentixafor, 
[68Ga]DOTATOC and [18F]FDG 
Synthesis of [68Ga]Pentixafor was performed by 
means of a fully GMP compliant automated 
synthesizer (GRP, Scintomics, Germany) [18, 25]. 
[18F]FDG and [68Ga]DOTATOC were prepared as 
previously described [26, 27].  
PET Imaging  
All PET/CT scans were performed on a 
dedicated PET/CT scanner (Siemens Biograph mCT 
64; Siemens Medical Solutions, Germany) within a 
median of 8 days (range, 1-64). Before acquisition of 
[18F]FDG-PET, patients fasted for at least 6 h and 
blood glucose levels were <160 mg/dl. Prior to 
[68Ga]DOTATOC and [68Ga]Pentixafor scans, no 
fasting was necessary. Imaging was performed 60 
minutes after injection of 57 to 140 MBq (median, 120 
MBq) of [68Ga]Pentixafor, 269 to 325 MBq (median, 
300 MBq) of [18F]FDG and 46 to 181 MBq (median, 137 
MBq) of [68Ga]DOTATOC, respectively. Spiral CT 
with (dose modulation with a quality reference of 210 
mAs, for [18F]FDG-PET/CT scans) or without (80mAs, 
120 kV, 512 x 512 matrix, 5 mm slice thickness) 
intravenous contrast including a field of view from 
the base of the skull to the proximal thighs was 
acquired. Consecutively, PET emission data were 
acquired in three-dimensional mode with a 200 × 200 
matrix with 2–3 min emission time per bed position. 
After decay and scatter correction, PET data were 
reconstructed iteratively with attenuation correction 
using the algorithm implemented by the 
manufacturer (Siemens Esoft, Siemens, Erlangen, 
Germany). 
Image Analysis  
All PET scans were first visually rated by three 
experienced nuclear medicine physicians (CL, RAW, 
JSS) in a binary fashion as positive or negative for 
disease. Lesions were visually determined as focally 
increased tracer retention as compared to 
surrounding normal tissue or normal contralateral 
structures. Presence and number of metastases as well 
as location of lesions (up to 50 lesions per system 
([nodal and/or hematogenous metastases]) were 
recorded. 
Semi-quantitative analysis was performed for 
the primary tumor (if present) as well as the hottest 
metastatic lymph node and organ lesion, respectively. 
The axial PET image slice displaying the maximum 
tumor uptake was selected by drawing a 3D-volume 





of interest (VOI) around the whole tumor area. Tumor 
regions of interest (ROIs) were defined in 2 ways. 
First, a standardized 10-mm circular region was 
placed over the area with the peak activity. This first 
ROI was used to derive maximum (SUVmax) and mean 
(SUVmean) standardized uptake values. A reference 
bloodpool region was defined by drawing a ROI 
(diameter of 20 mm) in the left ventricle of the heart to 
derive tumor-to-background ratios (TBR). TBR for 
SUVmax and SUVmean of all three tracers were 
calculated analyzing the primary (if still present), the 
hottest lymph node (LN) as well as visceral metastasis 
(M): Primarymax/Backgroundmean (Pmax/Bmean) and 
Primarymean/Backgroundmean (Pmean/Bmean); 
LNmax/Backgroundmean (LNmax/Bmean) and 
LNmean/Backgroundmean (LNmean/Bmean); 
Mmax/Backgroundmean (Mmax/Bmean) and 
Mmean/Backgroundmean (Mmean/Bmean). The radiotracer 
concentration in the ROIs was normalized to the 
injected dose per kilogram of patient’s body weight to 
derive the SUVs. 
Histological characterization of tumors 
Immunohistochemistry was carried out on 10% 
formalin fixed paraffin embedded tissue sections 
(3µm) according to established protocols and scored 
as previously described [28]. CXCR4- 
immunohistochemistry was performed using an 
anti-CXCR4 rabbit polyclonal antibody (ab2074; 
Abcam, Cambridge, United Kingdom) followed by 
detection with the DAKO en vision system according 
to the manufacturer’s protocol. 
For assessment of SSTR expression, polyclonal 
antibodies against SSTR2a (1:500, RBK 046-05, 
Zytomed, Berlin, Germany) and SSTR5 (1:500, RBK 
051-05, Zytomed, Berlin, Germany) were used. 
Samples from normal pancreatic tissue were used as 
positive control (islet cells). Dewaxed samples were 
pretreated with citrate buffer pH 6.0 for 10 minutes 
(for SSTR2a staining) or with the antigen retrieval 
agent TIRS-EDTA pH 9.0, respectively, for 10 minutes 
in a high pressure cooker (for SSTR5 staining). All 
immunostained sections were counterstained for 3 
minutes with hematoxylin. The analysis of the stained 
sections was done semi-quantitatively by 
light-microscopy according to the immunoreactive 
score (IRS) by Remmele and Stegner [29]. The 
percentage of CXCR4-/SSTR-positive cells was scored 
as follows: 0 (no positive cells), 1 (<10% positive cells), 
2 (10-50% positive cells), 3 (>50-80% positive cells), 4 
(>80% positive cells). Additionally, the intensity of 
staining was graded: 0 (no color reaction), 1 (mild 
reaction), 2 (moderate reaction), 3 (intense reaction). 
Multiplication of both scores for a given sample yields 
the IRS classification: 0-1 (negative), 2-3 (mild), 4-8 
(moderate), 9-12 (strongly positive).  
Statistical Analysis 
All results are displayed as mean ± SD or as 
median + range where appropriate.  
Results 
Clinical findings 
4/12 patients suffered from ileum NET, 3/12 
from pancreatic NET, 2/12 from gastric NET, and 
1/12 from rectum NET, esophageal NET and mixed 
adenoneuroendocrine carcinoma (MANEC, 
neuroendocrine component > 60%) of the colon, 
respectively. At the time point of imaging, 4/12 
subjects presented with newly diagnosed disease, the 
remainder (8/12) had already undergone various 
therapies including surgery (3/12), somatostatin 
analogs (3/12), conventional chemotherapy (3/12; 
2/3, streptozocin/5-fluorouracil; 1/3, carboplatin/ 
etoposide), peptide receptor radionuclide therapy 
(1/12) and transarterial chemoembolization (1/12).  
The primary tumor was still present in 9/12 
(75%) subjects. 11/12 patients presented with 
metastatic disease. Metastatic sites included liver 
(8/12), lymph nodes (LN; 7/12), bone (2/12), 
peritoneum (2/12), soft tissue (1/12) and lung (1/12).  
Proliferation index Ki67 ranged from 1-90% with 
a median of 10%. According to the ENETS, AJCC, and 
the 2010 WHO classification, 3/12 cases could be 
classified as G1, 4/12 as G2 and 5/12 as G3 NETs 
[30-32]. Of note, all G3 NETs presented with a Ki67 
index ≥60%.  
Clinical characteristics of the patient cohort are 
given in Table 1. 
Imaging results of the whole cohort 
On a patient basis, [68Ga]Pentixafor was visually 
rated positive in 6/12 subjects (50%), whereas 
[18F]FDG revealed sites of disease in 10/12 (83.3%) 
and [68Ga]DOTATOC in 11/12 patients (91.7%), 
respectively (Figure 1A).  
On a lesion basis, [68Ga]Pentixafor detected a 
total of 69 lesions (5 primary tumors, 22 LN, 1 bone, 41 
liver metastases) as opposed to 127 (5 primary tumors, 
60 LN, 1 bone, 61 liver metastases) for [18F]FDG and 
245 (5 primary tumors, 151 liver, 51 bone, 33 LN, 4 










Table 1. Detailed patient characteristics 
CLINICAL DATA PET Histology/ IHC 





























#1 m 76 gastric 0 liver CTx 60 3 - + - 32 liver 0 0 1 
#2 m 68 ileum 0 liver, LN SSA 10 2 + + + 218 liver 0 12 0 
#3 m 67 pancreatic 0 LN none 85 3 + + + 18 pancreas 9 12 3 
#4 f 48 pancreatic 0 liver SSA, CTx, 
PRRT 
10 2 + + + 930 pancreas 2 12 0 
#5 m 82 ileum 0 liver SSA, TAE 5 2 + + - 389 liver 0 12 4 
#6 m 65 pancreatic 2 none CTx 8 2 + - - 251 pancreas 0 12 2 
#7 m 80 ileum 2 LN, liver, 
peritoneum 
surgery 2 1 + + - 8 liver 0 12 12 
#8 m 55 esophageal 3 LN, liver, 
bone 
none 90 3 + + + 20 esophagus 2 0 0 
#9 m 76 rectum 1 LN, liver, 
bone, soft 
tissue 
none 2 1 + + - 89 rectum 1 9 3 
#10 m 74 ileum 1 peritoneum surgery 1 1 + - - 68 Ileum 0 8 4 
#11 m 67 gastric 2 LN, liver, 
lung 
none 90 3 + + + 18 stomach 2 0 12 
#12 f 67 colon 
(MANEC)* 
2 LN surgery 90 3 + + + 49 colon 0 0 12 
Bx = biopsy, CTx = chemotherapy, d = days, DOTATOC = DOTA-D-Phe-Tyr3-octreotide, ECOG = Easten Cooperative Oncology Group, FDG = fluorodeoxyglucose, f = 
female, IRS = immunoreactive score, LN = lymph node, m = male, MANEC = mixed adenoneuroendocrine carcinoma, PET = positron emission tomography, PRRT = peptide 




Figure 1. Visual comparison of [68Ga]Pentixafor, 68Ga-DOTA-D-Phe-Tyr3-octreotide ([68Ga]DOTATOC) and 18F-fluorodeoxy-glucose 
([18F]FDG) PET scans (whole cohort).The individual tracer´s superiority over another was defined on a per-lesion basis, i.e. the tracer depicting the highest 
number of tumor lesions was considered superior. Comparability of two tracers was present when both detected the same number of identical lesions. 
Complementarity was defined of presence of sites of disease exclusively detected by one of the two compared tracers, respectively. A. Number of patients with visual 
positivity for the indicated PET tracer (total, n=12). B. Number of patients (total, n=12) for whom imaging with [18F]FDG (n=7) or [68Ga]Pentixafor (n=3) was 
superior, with comparable positive findings (comparable, n=2) and with dual imaging providing no complementary information (complementary, n=0). C. Number of 
patients (total, n=12) for whom imaging with [68Ga]DOTATOC (n=6) or [68Ga]Pentixafor (n=4) was superior, with dual imaging providing complementary and 
comparable visual information in a single case each (complementary, n=1; comparable, n=1). D. Number of patients (total, n=12) for whom imaging with [18F]FDG 
(n=5) or [68Ga]DOTATOC (n=4) was superior, with comparable positive findings (comparable, n=2) and with dual imaging providing complementary visual 
information (complementary, n=1).  





Table 2. Display of mean (SUVmean) and maximum (SUVmax) standardized uptake values (and corresponding median) for [68Ga]Pentixafor, 
68Ga-DOTA-D-Phe-Tyr3-octreotide ([68Ga]DOTATOC) and 18F-fluorodeoxy-glucose ([18F]FDG). 
Grade Ki67(%) Patient [68Ga]DOTATOC [18F]FDG [68Ga]Pentixafor 
Pmax Pmean LNmax LNmean Mmax Mmean Pmax Pmean LNmax LNmean Mmax Mmean Pmax Pmean LNmax LNean Mmax Mmean 
1 1 #10 - - - - 14.3 12.9 - - - - - - - - - - - - 
1 2 #7 - - 73.9 60.8 - - - - 6.9 4.9 - - - - - - - - 
1 2 #9 - - - - 60.9 44.1 - - - - 9.1 6.5 - - - - - - 
Median of G1 NET - - 73.9 60.8 37.6 28.5 - - 6.9 4.9 9.1 6.5 - - - - - - 
2 5 #5 - - - - 20 19.4 - - - - 9 7 - - - - - - 
2 8 #6 41 31.2 - - - - - - - - - - - - - - - - 
2 10 #2 19.8 13.8 25.8 20.4 31.2 16.8 4.8 3.8 5.9 4.7 4.5 4.1 6.4 3.8 - - - - 
2 10 #4 87.8 55.1 - - 44.6 40.4 36.8 29.8 - - 43.6 36.7 8.7 5.2 - - 8.6 6 
Median of G2 NET 41 31.2 25.8 20.4 37.9 28.6 20.8 16.8 5.9 4.7 24.1 20.4 7.6 4.5 - - 8.6 6 
3 60 #1 - - - - - - - - - - 15 12.7 - - - - - - 
3 85 #3 15.5 9.7 13.7 8.3 - - 6.5 5.3 - - - - 10.2 6 9.7 5.8 - - 
3 90 #8 - - - - 8 5.5 17.2 6.3 10.8 10 20.7 9.6 7.2 3.7 9.3 4.3 10.5 4.9 
3 90 #11 30.5 21.9 - - - - 9.2 5.2 4.3 3.3 11.1 6.8 8.7 4.5 7.9 3.6 15.8 9.5 
3 90 #12 - - 6 3.4 - - - - 25.8 8.7 - - - - 5.7 3.5 - - 




Figure 2. Tumor heterogeneity in a patient with a G3 gastric neuroendocrine tumor (NET) and liver metastases (patient #11; Ki67: 90%). In 
accordance with G3 NET, hypermetabolic hepatic metastases demonstrate loss of somatostatin receptor (SSTR) and up-regulation of CXCR4 expression (solid 
arrows, corresponding SUVmax: 10.3 for [68Ga]Pentixafor, and 3.8 for [68Ga]DOTATOC, respectively). Moreover, [68Ga]Pentixafor provides additional information 
on disease extent by exclusively detecting a coeliacal lymph node suspicious for metastatic disease (dotted arrows). All transaxial PET/(CT) images are displayed 
identically with a window level between 0 and 5.5. [68Ga]DOTATOC = 68Ga-DOTA-D-Phe-Tyr3-octreotide, [18F]FDG = 18F-fluorodeoxy-glucose. 
 





Table 3. Heterogeneity of NET biology, as indicated by PET. In G1 NET, the vast majority of lesions showed sole expression of SSTR2, 
as indicated by focal retention of [68Ga]DOTATOC (104 lesions), and only few (11 lesions) concurrent glucose use, as indicated by 
[18F]FDG-PET. No lesion was positive at [68Ga]Pentixafor PET indicating no CXCR4 expression. In G3 NET, the vast majority of lesions 
revealed various combinations of SSTR and CXCR4 expression with or without deregulated glucose use. 
G1 NET [68Ga]DOTATOC [18F]FDG [68Ga]Pentixafor 
[68Ga]DOTATOC 104 11 0 
[18F]FDG - 0 0 
[68Ga]Pentixafor - - 0 
G2 NET [68Ga]DOTATOC [18F]FDG [68Ga]Pentixafor 
[68Ga]DOTATOC 107 10 3 
[18F]FDG - 3 3 
[68Ga]Pentixafor - - 0 
G3 NET [68Ga]DOTATOC [18F]FDG [68Ga]Pentixafor 
[68Ga]DOTATOC 0 11 12 
[18F]FDG - 47 56 
[68Ga]Pentixafor - - 9 
Since some lesions were positive for all three tracers, the sum of lesions can exceed the number given in the manuscript. [68Ga]DOTATOC = 
68Ga-DOTA-D-Phe-Tyr3-octreotide, [18F]FDG = 18F-fluorodeoxy-glucose. 
 
 
[68Ga]Pentixafor and [68Ga]DOTATOC were 
concordantly positive in not more than 15 lesions (4 
primary tumors, 9 LN, 1 bone and 1 liver lesion). 230 
[68Ga]DOTATOC-positive foci (1 primary tumor, 24 
LN, 150 liver metastases, 50 bone metastases, 1 soft 
tissue metastasis and 4 peritoneal lesions) were 
missed by [68Ga]Pentixafor; 54 lesions (1 primary 
tumor, 13 LN, 40 liver metastases) were 
CXCR4-positive and SSTR-negative. 
In semi-quantitative analysis, [68Ga]Pentixafor- 
PET-derived SUV and TBR were comparable to those 
calculated for [18F]FDG-PET. Corresponding 
individual values for all tracers are given in Table 2 
and Supplementary Table 1. 
Imaging results by tumor grade 
G1 NET 
All G1 NET (n=3) were [68Ga]DOTATOC- 
positive and [68Ga]Pentixafor-negative. [18F]FDG-PET 
yielded positive results in 2/3 patients. 
[68Ga]DOTATOC-PET returned a total of 115 NET 
lesions (10 LN, 50 bone, 50 liver, 4 peritoneal, and 1 
soft tissue metastases) as compared to 11 ([18F]FDG; 1 
LN, 10 liver metastases) and 0 ([68Ga]Pentixafor), 
respectively. [68Ga]DOTATOC was the superior 
radiotracer in all cases. [68Ga]Pentixafor did not yield 
additional or complementary information in any of 
those patients.  
G2 NET 
All G2 NET (n=4) were both SSTR- and 
[18F]FDG-positive, whereas CXCR4-positivity could 
only be observed in half of the cases (2/4). In parallel 
to G1 NET, [68Ga]DOTATOC-PET revealed the 
highest number of sites of disease in all but one 
subject (patient #4) with a total of 118 lesions (3 
primary tumors, 14 LN, 101 liver metastases), 
followed by [18F]FDG- (n=13; 2 primary tumors, 3 LN, 
8 liver metastases) and [68Ga]Pentixafor-PET (n=3; 2 
primary tumors, 1 liver metastasis). [68Ga]Pentixafor 
did not yield additional or complementary 
information in any patient. 
G3 NET 
Investigating G3 NET, 5/5 subjects were rated 
[18F]FDG positive. CXCR4- and SSTR-PET identified 
lesions in 4/5 patients each. On a lesion basis, 
[18F]FDG revealed the highest number of metastases 
in 3/5, [68Ga]Pentixafor in the remaining 2/5 subjects. 
In total, [18F]FDG-PET detected 103 sites of disease (3 
primary tumors, 56 LN, 1 bone, 43 liver metastases), 
followed by [68Ga]Pentixafor- (n=66; 3 primary 
tumors, 22 LN, 1 bone, 40 liver metastases) and 
[68Ga]DOTATOC-PET (n=12; 2 primary tumors, 9 LN, 
1 bone metastasis). 
The number of positive lesions for each PET 
tracer according to grading is given in Table 3. 
Immunohistochemistry 
Imaging results were compared to 
immunohistological staining for SSTR2a/5 and 
CXCR4 derived from biopsies of the primary tumor 
(n=8) or metastases (n=4). Regarding the histological 
evaluation of CXCR4 expression, 4/12 samples were 
rated “mild” (IRS 2, patient #4, #8, #9, and #11) and 
1/12 “strongly” (IRS 9, patient #3, Figure 3) positive. 
Of note, relevant receptor expression on the cell 
surface could only be detected in 3 patients (patients 
#3, #8, #11), whereas CXCR4 was located 
intracytoplasmatic in the remaining 2 subjects. The 
remaining 7/12 samples (patients #1, 2, 5, 6, 7, 10, 12) 
were scored negative.  
When imaging was performed, the site of 
histology was still present in 9/12 subjects (6 primary 
tumors [patients #3, #4, #6, #8, #9, #11], 3 liver 
metastases [patients #1, #2, #5]). [68Ga]Pentixafor 
uptake of the respective lesion was substantially 





corroborated by histology in 8/9 subjects (except 
patient #9 with an IRS of 1 and a negative 
[68Ga]Pentixafor-PET). As a sign of intra-individual 
heterogeneity, whole-body imaging differed from 
sample-based immunohistological CXCR4 score as 
two patients with CXCR4-negative tumor samples 
(patients #2, #12) presented with –in patient-based 
analysis- positive [68Ga]Pentixafor-PET scans. 
Interestingly, both subjects presented with 
heterogeneous, rather low tracer uptake with a 
SUVmax<6.5 (Figure 4). 
In comparison, SSTR2a expression was rated 
“negative” in 4/12, “moderate” in 2/12 (patients #9, 
10) and “strongly” positive in 6/12. SSTR5 was 
“mildly” positive in 3/12, “moderate” in 2/12 and 




Figure 3. Concordance of immunohistochemistry and non-invasive receptor-directed PET imaging in a patient with pancreatic neuroendocrine 
tumor (NET; patient #3; Ki67: 85%). Display of transaxial PET (left) and fused PET/CT (middle) images of the primary tumor in the major pancreatic papilla 
(papilla of Vater; papilla vateri). The NET demonstrates high expression of both SSTR2a and CXCR4 which could be confirmed in the surgical specimen after tumor 
resection (right). Interestingly, CXCR4-PET correctly identified three additional lymph node metastases (versus none in [18F]FDG- and a single metastasis in 
SSTR-directed PET, Supplementary Figure 1). All PET/(CT) images are displayed identically with a window level between 0 and 5.5. [18F]FDG = 
18F-fluorodeoxy-glucose, [68Ga]DOTATOC = 68Ga-DOTA-D-Phe-Tyr3-octreotide. 
 
 
Figure 4. Lesional heterogeneity of CXCR4 expression in neuroendocrine tumor (NET). Display of 2 patients with G2 NET of the ileum (patient #2, 
Ki67: 10%) and G3 mixed adenoneuroendocrine carcinoma (MANEC, patient #12, Ki67: 90%), respectively. Both patients presented with negative 
immunohistochemistry (IHC) for CXCR4. As a possible explanation, [68Ga]Pentixafor-PET imaging revealed very low, heterogeneous chemokine receptor 
expression (arrows) which might differ from the site of histology (liver and colon, respectively). 






This is the first report of non-invasive 
assessment of CXCR4 expression in GEP-NET. In the 
present cohort, CXCR4 expression could be visualized 
in patients with high-grade G3 neuroendocrine 
carcinomas. Of note, the majority of the 
[68Ga]Pentixafor-positive subjects presented with 
highly proliferative disease with Ki67 of ≥85%, 
whereas well-differentiated tumors did not 
demonstrate relevant receptor expression on the cell 
surface.  
[68Ga]Pentixafor-PET findings could be 
corroborated by [18F]FDG-PET and somatostatin 
receptor PET imaging: Whereas all CXCR4-positive 
subjects also demonstrated high [18F]FDG uptake, 
SSTR expression as assessed by [68Ga]DOTATOC was 
rather low or even absent. 
These results are in line with a recent analysis of 
surgical GEP-NET samples reporting on an inverse 
expression of SSTR2 and CXCR4 in G1 to G3 NETs 
with an elevation in CXCR4 and a decrease in SSTR2a 
expression with increasing grade [10].  
As expected, relevant SSTR expression could be 
mainly found in G1 and G2 NETs whereas most of the 
G3 NET lesions proved SSTR-negative. Whereas the 
recent NETTER-1 trial emphasized the paramount 
importance of peptide receptor radionuclide therapy 
for SSTR-positive tumors [6], molecular imaging or 
treatment with radiolabeled SSTR analogs is generally 
not useful for G3 tumors, which rarely express these 
receptors in an appropriate frequency and magnitude 
[7]. The mainstay of treatment for poorly 
differentiated NET consists of a platinum-based 
chemotherapeutic regimen which has proven high 
initial response rates of up to 80% [33]. However, as 
compared to small cell lung cancer, duration of 
response is rather limited with 8-11 months [34] and 
treatment options after failure of 1st-line 
chemotherapy are limited. Given the rather robust 
receptor expression in G3 NET, targeting of CXCR4 
emerges as a promising new therapeutic approach for 
these patients. Recently, feasibility of CXCR4-directed 
ERT has been successfully demonstrated in the 
treatment of multiple myeloma and other hematologic 
malignancies [16]. Importantly, given the relevant 
hematotoxicity resulting in bone marrow ablation, 
autologous stem cell support is mandatory in all 
potential ERT candidates before therapy can be 
considered. Since most of the patients in whom 
CXCR4-directed ERT might become an option (G3 
NET) receive hematotoxic standard chemotherapeutic 
regimens (platinum/etoposide) as first-line treatment, 
identification of sufficient receptor expression early in 
the course of treatment is essential in order not to 
harm successful stem cell mobilization. However, if 
stem cells are available, ERT is easily performed and 
has been well-tolerated without any relevant further 
adverse effects [16]. 
Interestingly, distinct intra-individual tumor 
heterogeneity could be demonstrated in this cohort 
with the majority of patients displaying lesions with 
varying PET positivity. Whereas the notion of 
different patterns of [18F]FDG and [68Ga]DOTATOC 
positivity is well-known and has been described in a 
number of studies [9, 35], the current project adds to 
the complexity of tumor biology: Whereas a relevant 
number of lesions with elevated glucose consumption 
did not overexpress CXCR4 on the cell surface, other 
lesions concordantly demonstrated [18F]FDG as well 
as chemokine receptor accumulation. This 
observation might be especially interesting for G2 
NET patients in whom CXCR4 positivity might 
denote more aggressive disease.  
On the other hand, tumor heterogeneity is an 
important factor when ERT eligibility is assessed. 
Since ERT will only be effective if (nearly) all lesions 
are addressed, pre-therapeutic comparison of 
[68Ga]Pentixafor with [18F]FDG is mandatory not to 
miss a relevant subset of CXCR4-negative lesions. 
The underlying mechanisms or prognostic value 
of those different lesions and how these lesions 
respond to current treatments has not been clarified 
yet. For a deeper understanding of the underlying 
biology, PET guided biopsies of lesions with 
divergent tracer uptake (and therefore different 
biology) will be performed at our center to gain 
additional insights into heterogeneity.  
Further prospective studies also regarding the 
prognostic value of CXCR4-expressing disease in 
terms of therapy monitoring are highly warranted. 
Another unsolved question refers to potential 
synergistic combinations of various therapeutic 
agents and their effect on CXCR4 surface expression. 
Our group has experienced downregulation or loss of 
receptor shortly after initiation of anti-tumor therapy 
in small cell lung cancer patients [22]. Given the 
obvious pressure to start anti-tumor therapy in 
patients with advanced, highly aggressive disease, 
future studies will need to further investigate 
therapy-induced down- and, -preferably-, 
up-regulation of CXCR4. Potentially, a sequential 
combination with chemotherapeutic agents might 
lead to improved efficacy of CXCR4-directed ERT.  
This study has several limitations. Because of the 
retrospective nature of the study, the statistical power 
is limited, also due to the relatively small sample size. 
Secondly, biopsies were not always obtained on a 
short-term period compared to the time point of PET 
imaging. Hence, correlation between histology and 





imaging-derived receptor expression gives rise to 
significant bias, given the fact that receptor expression 
and functionality is subject to significant fluctuations. 
Additionally, histological confirmation of lesions with 
discordant tracer uptake (e.g. exclusive 
[68Ga]Pentixafor uptake) to rule out false positive 
imaging results was not available in all cases. Finally, 
although a general agreement between histology and 
imaging could be demonstrated, [68Ga]Pentixafor PET 
uptake seemed not to be corroborated by 
immunohistochemical findings in some cases. Of 
note, CXCR4 receptor expression is a dynamic process 
which can be influenced by a number of factors 
including therapies. [68Ga]Pentixafor only addresses 
the receptors which are presented on the cell surface, 
whereas the cytoplasmatic or nucleic compartment 
cannot be addressed. Additionally, tumor biopsy 
samples are per se prone to sampling bias and cannot 
reflect the whole-body information derived by 
PET/CT imaging. Further studies to investigate 
down- and –preferably- up-regulation of CXCR4 are 
warranted. 
Conclusion 
Whereas CXCR4 expression seems to play only a 
limited role in well-differentiated NET, increasing 
receptor expression could be non-invasively observed 
with increasing tumor grade. Thus, [68Ga]Pentixafor 
PET/CT might serve as non-invasive read-out for 
endoradiotherapy in advanced SSTR-negative, 
dedifferentiated tumors. 
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